Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 11 | 2023 | 61 | 3.480 |
Why?
|
| Community Pharmacy Services | 6 | 2022 | 25 | 3.440 |
Why?
|
| Pharmacy | 5 | 2023 | 34 | 2.830 |
Why?
|
| Pharmaceutical Services | 5 | 2023 | 25 | 2.470 |
Why?
|
| Pharmacies | 3 | 2023 | 23 | 2.210 |
Why?
|
| Students, Pharmacy | 3 | 2025 | 58 | 2.040 |
Why?
|
| Atrial Fibrillation | 6 | 2018 | 122 | 1.680 |
Why?
|
| Professional Role | 6 | 2022 | 40 | 1.610 |
Why?
|
| Pulmonary Embolism | 4 | 2018 | 38 | 1.270 |
Why?
|
| Asthma | 4 | 2020 | 416 | 1.170 |
Why?
|
| Cost-Benefit Analysis | 3 | 2018 | 179 | 1.110 |
Why?
|
| Telemedicine | 2 | 2020 | 234 | 1.000 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 310 | 0.990 |
Why?
|
| Humans | 46 | 2025 | 43102 | 0.910 |
Why?
|
| Civil Defense | 1 | 2025 | 17 | 0.880 |
Why?
|
| Disaster Planning | 1 | 2025 | 62 | 0.840 |
Why?
|
| Stroke | 5 | 2018 | 340 | 0.760 |
Why?
|
| Case Management | 1 | 2022 | 24 | 0.740 |
Why?
|
| Health Facilities | 1 | 2022 | 32 | 0.730 |
Why?
|
| Warfarin | 3 | 2018 | 67 | 0.730 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 58 | 0.700 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 24 | 0.700 |
Why?
|
| Research Personnel | 1 | 2023 | 206 | 0.690 |
Why?
|
| Health Care Costs | 2 | 2019 | 91 | 0.690 |
Why?
|
| Influenza, Human | 1 | 2022 | 92 | 0.680 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2020 | 5 | 0.670 |
Why?
|
| Hospital Mortality | 3 | 2017 | 210 | 0.660 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 52 | 0.630 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 760 | 0.630 |
Why?
|
| Ambulatory Care | 1 | 2020 | 81 | 0.620 |
Why?
|
| Drugs, Generic | 1 | 2019 | 6 | 0.610 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 9 | 0.610 |
Why?
|
| Prescription Drugs | 1 | 2019 | 32 | 0.590 |
Why?
|
| Benzazepines | 2 | 2016 | 33 | 0.590 |
Why?
|
| Internship and Residency | 1 | 2020 | 146 | 0.580 |
Why?
|
| Social Values | 1 | 2018 | 31 | 0.580 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 539 | 0.560 |
Why?
|
| Stroke Volume | 2 | 2016 | 122 | 0.560 |
Why?
|
| United States | 11 | 2023 | 5205 | 0.560 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 26 | 0.540 |
Why?
|
| Glucosides | 1 | 2017 | 21 | 0.540 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 25 | 0.530 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 73 | 0.530 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 48 | 0.520 |
Why?
|
| Benzhydryl Compounds | 1 | 2017 | 50 | 0.520 |
Why?
|
| Quality of Life | 2 | 2020 | 616 | 0.520 |
Why?
|
| Observation | 1 | 2017 | 10 | 0.520 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2016 | 14 | 0.510 |
Why?
|
| Drug Prescriptions | 2 | 2016 | 60 | 0.500 |
Why?
|
| Hospitalization | 2 | 2018 | 485 | 0.500 |
Why?
|
| Resource Allocation | 1 | 2016 | 14 | 0.480 |
Why?
|
| Aged | 12 | 2024 | 8214 | 0.480 |
Why?
|
| Cardiovascular Diseases | 3 | 2017 | 749 | 0.480 |
Why?
|
| Patient Admission | 1 | 2016 | 50 | 0.470 |
Why?
|
| Thiazoles | 1 | 2016 | 76 | 0.470 |
Why?
|
| Pyridones | 1 | 2016 | 50 | 0.470 |
Why?
|
| Tetrazoles | 1 | 2015 | 46 | 0.470 |
Why?
|
| Databases, Factual | 1 | 2017 | 341 | 0.470 |
Why?
|
| Pyrazoles | 1 | 2016 | 103 | 0.460 |
Why?
|
| Pyridines | 1 | 2016 | 139 | 0.450 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 104 | 0.440 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 3156 | 0.430 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2016 | 92 | 0.430 |
Why?
|
| Treatment Outcome | 6 | 2018 | 1604 | 0.410 |
Why?
|
| Smoking Cessation | 1 | 2020 | 590 | 0.400 |
Why?
|
| Idaho | 3 | 2024 | 5 | 0.390 |
Why?
|
| Heart Failure | 1 | 2015 | 302 | 0.360 |
Why?
|
| Workflow | 2 | 2021 | 26 | 0.340 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2020 | 22 | 0.330 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2020 | 8 | 0.320 |
Why?
|
| Female | 17 | 2024 | 24698 | 0.310 |
Why?
|
| Male | 15 | 2024 | 23409 | 0.300 |
Why?
|
| Anticoagulants | 4 | 2018 | 122 | 0.290 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2018 | 44 | 0.270 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 64 | 0.270 |
Why?
|
| Markov Chains | 2 | 2018 | 43 | 0.270 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2017 | 75 | 0.250 |
Why?
|
| Chronic Disease | 2 | 2023 | 549 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 223 | 0.240 |
Why?
|
| Risk Assessment | 6 | 2018 | 863 | 0.240 |
Why?
|
| Vaccination | 3 | 2022 | 355 | 0.230 |
Why?
|
| Curriculum | 2 | 2025 | 318 | 0.220 |
Why?
|
| Prospective Studies | 3 | 2018 | 1600 | 0.220 |
Why?
|
| Educational Measurement | 1 | 2025 | 102 | 0.210 |
Why?
|
| Educational Status | 2 | 2023 | 339 | 0.210 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 259 | 0.210 |
Why?
|
| Education, Pharmacy | 1 | 2025 | 57 | 0.210 |
Why?
|
| Middle Aged | 6 | 2024 | 12222 | 0.200 |
Why?
|
| Empyema, Pleural | 1 | 2022 | 2 | 0.190 |
Why?
|
| Pleural Effusion | 1 | 2022 | 8 | 0.190 |
Why?
|
| Pleural Diseases | 1 | 2022 | 3 | 0.190 |
Why?
|
| Credentialing | 1 | 2022 | 3 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 234 | 0.190 |
Why?
|
| Immunization Programs | 1 | 2022 | 25 | 0.190 |
Why?
|
| Immunization | 1 | 2022 | 94 | 0.180 |
Why?
|
| Hemorrhage | 2 | 2022 | 55 | 0.180 |
Why?
|
| Dietetics | 1 | 2022 | 23 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2022 | 47 | 0.180 |
Why?
|
| Retrospective Studies | 5 | 2022 | 2544 | 0.170 |
Why?
|
| Insurance, Health | 1 | 2022 | 145 | 0.170 |
Why?
|
| Rural Population | 1 | 2024 | 373 | 0.170 |
Why?
|
| Washington | 1 | 2020 | 38 | 0.170 |
Why?
|
| Authorship | 1 | 2020 | 6 | 0.170 |
Why?
|
| Medicare | 2 | 2021 | 332 | 0.170 |
Why?
|
| Oregon | 1 | 2020 | 64 | 0.170 |
Why?
|
| Publications | 1 | 2020 | 10 | 0.170 |
Why?
|
| New Mexico | 1 | 2020 | 37 | 0.170 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2020 | 18 | 0.170 |
Why?
|
| Bibliometrics | 1 | 2020 | 16 | 0.170 |
Why?
|
| Workload | 1 | 2020 | 25 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2023 | 574 | 0.160 |
Why?
|
| Health Care Surveys | 1 | 2020 | 152 | 0.160 |
Why?
|
| Mass Screening | 1 | 2024 | 541 | 0.160 |
Why?
|
| Health Personnel | 1 | 2022 | 277 | 0.150 |
Why?
|
| Adult | 5 | 2024 | 13872 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 719 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 112 | 0.140 |
Why?
|
| Crataegus | 1 | 2018 | 2 | 0.140 |
Why?
|
| Muscarinic Antagonists | 1 | 2018 | 11 | 0.140 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2018 | 27 | 0.140 |
Why?
|
| Thrombectomy | 1 | 2018 | 12 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 375 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2018 | 29 | 0.140 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 37 | 0.140 |
Why?
|
| Drug Costs | 1 | 2017 | 35 | 0.130 |
Why?
|
| Morbidity | 1 | 2017 | 97 | 0.130 |
Why?
|
| Oculomotor Nerve | 1 | 2017 | 4 | 0.130 |
Why?
|
| Oculomotor Muscles | 1 | 2017 | 14 | 0.130 |
Why?
|
| Eye Movements | 1 | 2017 | 16 | 0.130 |
Why?
|
| Electrocardiography | 1 | 2018 | 185 | 0.130 |
Why?
|
| Amiodarone | 1 | 2016 | 2 | 0.130 |
Why?
|
| Neoplasms | 2 | 2018 | 1377 | 0.130 |
Why?
|
| Heart | 1 | 2018 | 184 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 2853 | 0.120 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2016 | 54 | 0.120 |
Why?
|
| Public Health | 1 | 2020 | 424 | 0.120 |
Why?
|
| Recurrence | 1 | 2016 | 152 | 0.120 |
Why?
|
| Immune System Diseases | 1 | 2016 | 21 | 0.120 |
Why?
|
| Neprilysin | 1 | 2015 | 8 | 0.120 |
Why?
|
| Brain Ischemia | 1 | 2018 | 189 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 440 | 0.120 |
Why?
|
| Biphenyl Compounds | 1 | 2015 | 53 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 78 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2015 | 104 | 0.120 |
Why?
|
| Physicians | 1 | 2017 | 188 | 0.110 |
Why?
|
| Risk Factors | 3 | 2018 | 3994 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2018 | 302 | 0.110 |
Why?
|
| Heart Rate | 1 | 2016 | 266 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 638 | 0.110 |
Why?
|
| Comorbidity | 1 | 2017 | 737 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2016 | 182 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2018 | 1759 | 0.100 |
Why?
|
| Child | 1 | 2022 | 3443 | 0.100 |
Why?
|
| Trigeminal Neuralgia | 1 | 2012 | 1 | 0.100 |
Why?
|
| Young Adult | 3 | 2024 | 5080 | 0.090 |
Why?
|
| Health Behavior | 1 | 2016 | 575 | 0.090 |
Why?
|
| Time Factors | 1 | 2016 | 1857 | 0.090 |
Why?
|
| Adolescent | 2 | 2024 | 6081 | 0.080 |
Why?
|
| Behavior, Animal | 1 | 2012 | 373 | 0.080 |
Why?
|
| Administration, Inhalation | 2 | 2018 | 92 | 0.070 |
Why?
|
| Prognosis | 2 | 2018 | 861 | 0.060 |
Why?
|
| Incidence | 2 | 2018 | 1078 | 0.060 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 166 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 21 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 24 | 0.050 |
Why?
|
| Health Occupations | 1 | 2021 | 19 | 0.040 |
Why?
|
| Writing | 1 | 2020 | 42 | 0.040 |
Why?
|
| Alaska | 1 | 2020 | 62 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2022 | 231 | 0.040 |
Why?
|
| Faculty | 1 | 2020 | 105 | 0.040 |
Why?
|
| Mentors | 1 | 2020 | 145 | 0.040 |
Why?
|
| Peer Group | 1 | 2020 | 177 | 0.040 |
Why?
|
| Budesonide | 1 | 2018 | 5 | 0.040 |
Why?
|
| Equipment Safety | 1 | 2018 | 5 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2018 | 61 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 115 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 74 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 159 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 317 | 0.030 |
Why?
|
| Motor Neurons | 1 | 2017 | 90 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 151 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2020 | 380 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 224 | 0.030 |
Why?
|
| Axons | 1 | 2017 | 117 | 0.030 |
Why?
|
| Heart Failure, Systolic | 1 | 2016 | 4 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 2016 | 20 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 59 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 437 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 153 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 163 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 69 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 260 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1154 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1067 | 0.030 |
Why?
|
| Students | 1 | 2021 | 626 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 163 | 0.030 |
Why?
|
| Mice | 2 | 2017 | 6644 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 247 | 0.020 |
Why?
|
| Facial Pain | 1 | 2012 | 3 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 2012 | 14 | 0.020 |
Why?
|
| Trigeminal Nuclei | 1 | 2012 | 11 | 0.020 |
Why?
|
| Nociceptors | 1 | 2012 | 30 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2012 | 83 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 934 | 0.020 |
Why?
|
| Animals | 2 | 2017 | 16992 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 1869 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 1596 | 0.020 |
Why?
|